Biogen Inc (NASDAQ:BIIB) – Research analysts at Leerink Swann lowered their Q1 2017 earnings per share (EPS) estimates for Biogen in a note issued to investors on Tuesday, according to Zacks Investment Research. Leerink Swann analyst G. Porges now anticipates that the biotechnology company will post earnings of $4.47 per share for the quarter, down […] - From Markets Daily
Norges Bank bought a new stake in Biogen during the fourth quarter valued at about $603,929,000.
MD now owns 7,610,028 shares of the biotechnology company’s stock valued at $2,382,167,000 after buying an additional 1,243,876 shares in the last quarter.
The Manufacturers Life Insurance Company bought a new stake in Biogen during the third quarter valued at about $222,430,000.
DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main bought a new stake in Biogen during the fourth quarter valued at about $179,141,000.
Renaissance Technologies LLC now owns 707,495 shares of the biotechnology company’s stock valued at $200,631,000 after buying an additional 469,234 shares in the last quarter.